Trial Profile
Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Voriconazole
- Indications Candidaemia; Invasive candidiasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 06 Jul 2019 Results of post hoc pooled analysis determining the efficacy and safety of anidulafungin treatment in patients with intra abdominal candidiasis from five prospective studies (NCT00496197, NCT00548262, NCT00537329,NCT00689338 and NCT00805740) published in the European Journal of Clinical Microbiology and Infectious Diseases
- 29 May 2018 New trial record